Dynamics of Soluble Programmed Death-Ligand 1 (sPDL1) during Chemotherapy and Its Prognostic Implications in Cancer Patients: Biomarker Development in Immuno-oncology

PURPOSE: The soluble programmed death-ligand 1 (sPDL1) has immunosuppressive activity and is a candidate biomarker for immuno-oncology drug development. In this study, we measured sPDL1 at pre- and post-chemotherapy and at disease progression to uncover the dynamics of sPDL1 during treatment in bili...

Descripción completa

Detalles Bibliográficos
Autores principales: Ha, Hyerim, Bang, Ju-Hee, Nam, Ah-Rong, Park, Ji-Eun, Jin, Mei Hua, Bang, Yung-Jue, Oh, Do-Youn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6473273/
https://www.ncbi.nlm.nih.gov/pubmed/30309223
http://dx.doi.org/10.4143/crt.2018.311

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6473273/
https://www.ncbi.nlm.nih.gov/pubmed/30309223
http://dx.doi.org/10.4143/crt.2018.311

Ejemplares similares